三甲基-[3-(甲基氨基甲酰氧基)苯基]铵 | 17752-10-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 三甲基-[3-(甲基氨基甲酰氧基)苯基]铵
• 英文名称: N-monomethylneostigmine
• 英文别名: N-Methyl-carbaminsaeure-<3-trimethylammonio-ethylester>；Benzenaminium, N,N,N-trimethyl-3-(((methylamino)carbonyl)oxy)-；trimethyl-[3-(methylcarbamoyloxy)phenyl]azanium
• CAS: 17752-10-2
• 化学式: C₁₁H₁₇N₂O₂
• 分子量: 209.268
• InChiKey: NTUWKYJEWBGXQA-UHFFFAOYSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

文献信息

• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20110319386A1

  公开（公告）日：2011-12-29

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.
• [EN] NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION<br/>[FR] NEUROGÉNÈSE PAR UNE MODULATION D'UN RÉCEPTEUR MUSCARINIQUE
  申请人：BRAINCELLS INC

  公开号：WO2012170599A1

  公开（公告）日：2012-12-13

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.